Press release
Diabetic Macular Edema Market Set for Robust Growth Through 2036 as Long-Acting Therapies and Novel Anti-VEGF Innovations Transform Treatment Landscape
Diabetic Macular Edema (DME) continues to represent one of the leading causes of vision impairment among adults with diabetes, creating a significant clinical and economic burden worldwide. DelveInsight's "Diabetic Macular Edema (DME) Market Insights, Epidemiology and Market Forecast - 2036" report provides comprehensive insights into disease epidemiology, market dynamics, current treatment practices, marketed products, emerging therapies, and commercial opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
👉 Discover detailed market insights, epidemiology forecasts, and competitive intelligence in DelveInsight's latest Diabetic Macular Edema Market report:https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Highlights from the Diabetic Macular Edema Market Report
• The Diabetic Macular Edema market across the 7MM reached approximately USD 4.0 billion in 2025.
• The United States accounted for nearly USD 2.2 billion, representing around 60% of the total market.
• Approximately 900,000 diagnosed prevalent cases were reported across the 7MM in 2025.
• Anti-VEGF therapies continue to dominate the treatment landscape.
• Long-acting therapies, biosimilars, and novel retinal treatments are expected to reshape future market dynamics.
• Pipeline candidates including OCS-01, Restoret (MK-3000), and RG6351 are anticipated to strengthen the competitive landscape.
👉 Request a complimentary sample report to explore detailed forecasts, treatment algorithms, and emerging opportunities: https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Growing Disease Burden Continues to Drive Market Growth
Diabetic Macular Edema develops as a complication of diabetic retinopathy due to leakage from damaged retinal blood vessels, leading to retinal thickening and impaired central vision. Increasing diabetes prevalence, aging populations, obesity, hypertension, and improved screening programs continue to expand the diagnosed patient pool worldwide.
The growing adoption of Optical Coherence Tomography (OCT) has significantly improved early diagnosis, enabling timely treatment and better patient outcomes. These factors continue to support sustained market expansion throughout the forecast period.
Diabetic Macular Edema Recent Industry Developments
The DME market continues to witness rapid innovation through regulatory approvals and strategic collaborations.
• April 2026: Regeneron Pharmaceuticals received FDA approval to extend EYLEA dosing intervals up to every 20 weeks for eligible DME patients.
• February 2026: Sandoz expanded FDA approval for ENZEEVU, adding Diabetic Macular Edema among its retinal indications.
• February 2025: Roche obtained FDA approval for SUSVIMO, the first long-acting ocular implant for DME.
• Samsung Bioepis partnered with Harrow to commercialize OPUVIZ, an aflibercept biosimilar designed to improve affordability and patient access.
👉 Explore the latest regulatory updates, clinical developments, and commercialization strategies shaping the DME market: https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Diabetic Macular Edema Current Treatment Landscape
Current DME management is primarily driven by intravitreal anti-VEGF therapies, supported by corticosteroids and laser photocoagulation in selected patients.
Leading marketed therapies include:
• EYLEA (Aflibercept)
• LUCENTIS (Ranibizumab)
• VABYSMO (Faricimab)
• BEOVU (Brolucizumab)
• SUSVIMO (Ranibizumab Implant)
Long-acting drug delivery systems are helping reduce injection frequency while improving treatment adherence and long-term visual outcomes.
Diabetic Macular Edema Emerging Pipeline Offers Significant Commercial Opportunities
The DME pipeline continues to expand with innovative therapies designed to improve durability and overcome limitations associated with conventional anti-VEGF treatment.
Among the leading pipeline assets:
• OCS-01 (Oculis) - Phase III topical dexamethasone eye drops with the potential to become the first non-invasive DME therapy.
• Restoret (MK-3000) - Merck's investigational WNT pathway agonist targeting restoration of the blood-retinal barrier.
• RG6351 and several sustained-delivery biologics are expected to further diversify future treatment options.
👉 Gain comprehensive insights into the late-stage pipeline, clinical trials, and emerging therapies in the full report: https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Diabetic Macular Edema Competitive Landscape
The Diabetic Macular Edema market remains highly competitive with pharmaceutical companies investing heavily in retinal disease innovation.
Major companies include:
• Regeneron Pharmaceuticals
• Bayer
• Roche
• Genentech
• Novartis
• Merck
• Oculis
• Sandoz
Competition is expected to intensify with the introduction of biosimilars, bispecific antibodies, gene therapies, sustained-release technologies, and next-generation anti-VEGF therapies.
Market Outlook Through 2036
According to DelveInsight, the Diabetic Macular Edema market is expected to experience sustained growth through 2036. Increasing disease prevalence, expanding patient access, greater adoption of long-acting therapies, and continuous innovation in retinal therapeutics will remain key growth drivers.
The future treatment landscape is anticipated to shift toward personalized medicine, sustained drug delivery platforms, biosimilars, and therapies targeting mechanisms beyond VEGF inhibition, creating significant opportunities for pharmaceutical companies and investors alike.
👉 Read the complete Diabetic Macular Edema Market Forecast - 2036 to explore market size, epidemiology, treatment trends, competitive intelligence, and future commercial opportunities:
https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading healthcare market research and consulting firm specializing in life sciences. The company provides comprehensive market intelligence, epidemiology forecasts, competitive intelligence, pipeline analysis, pricing assessments, and strategic consulting services to pharmaceutical, biotechnology, and medical device organizations worldwide. Its extensive portfolio delivers actionable insights across therapeutic areas, enabling stakeholders to make informed business decisions and capitalize on emerging healthcare opportunities.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Macular Edema Market Set for Robust Growth Through 2036 as Long-Acting Therapies and Novel Anti-VEGF Innovations Transform Treatment Landscape here
News-ID: 4585620 • Views: …
More Releases from Delveinsight Business Research LLP
Hypertrophic Cardiomyopathy Market to Witness Strong Growth Through 2034 as Nove …
According to DelveInsight's latest analysis, the Hypertrophic Cardiomyopathy (HCM) Market is expected to experience significant growth through 2034, driven by rising disease awareness, advances in genetic diagnostics, increasing diagnosis rates, and the emergence of innovative disease-specific therapies.
Hypertrophic Cardiomyopathy (HCM) remains one of the most common inherited cardiovascular disorders, affecting thousands of patients across the seven major markets (7MM). Characterized by abnormal thickening of the heart muscle, HCM can lead to…
Paroxysmal Nocturnal Hemoglobinuria Market Expected to Surpass USD 1.5 Billion A …
According to DelveInsight's latest analysis, the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market is poised for steady growth through 2036, driven by increasing disease awareness, improved diagnostic capabilities, expanding use of targeted complement inhibitors, and a strong late-stage pipeline of innovative therapies.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by chronic intravascular hemolysis, bone marrow failure, and life-threatening thromboembolic complications. Although considered an ultra-rare disease, significant advances in complement…
Atopic Keratoconjunctivitis (AKC) Market Expected to Witness Steady Growth Throu …
The Atopic Keratoconjunctivitis (AKC) market is anticipated to witness notable growth across the Seven Major Markets (7MM) during the forecast period (2026-2036). Market expansion is expected to be driven by the increasing diagnosed patient population, growing awareness among ophthalmologists and dermatologists, improved recognition of severe ocular allergic diseases, and the anticipated introduction of targeted therapies designed to address chronic ocular inflammation. Although AKC remains a relatively uncommon disease, its vision-threatening…
Vasomotor Symptoms Market Expected to Grow Through 2036, Driven by Novel Non-Hor …
The Vasomotor Symptoms (VMS) market is anticipated to witness substantial growth across the Seven Major Markets (7MM) and the Rest of the World (ROW) during the forecast period (2026-2036). Market expansion is expected to be fueled by the growing menopausal population, increasing awareness of women's health, improved diagnosis, the launch of innovative non-hormonal therapies, and continued investments in women's healthcare. The emergence of novel neurokinin receptor antagonists and other targeted…
More Releases for Diabetic
Exploring The Diabetic Retinopathy Market In A Diabetic-Prevalent World: The Dri …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Diabetic Retinopathy Market Size Growth Forecast: What to Expect by 2025?
The diabetic retinopathy market has experienced robust expansion over the last few years, with projections indicating a rise from $8.61 billion in 2024 next year to $9.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of…
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
